By InvitationNot Applicable

Retrospective WGS Study

United Kingdom2,000 participantsStarted 2022-09-22

Plain-language summary

This retrospective case series reviews clinical notes to assess whether NHS whole genome sequencing provides tangible benefits for paediatric tumours.

Who can participate

Age range0 Years – 21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All children and young people (up to the age of 21 years) diagnosed with a neoplastic disorder who have been offered NHSE whole genome sequencing. Exclusion Criteria: * Anyone not offered NHSE whole genome sequencing * Individuals beyond the age of 21 * Individuals without a neoplastic disorder.

What they're measuring

The proportion of children clinically benefiting from whole genome sequencing

Timeframe: 5.5 years

Trial details

NCT IDNCT06820294

SponsorThe Wellcome Sanger Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-03-31

View on ClinicalTrials.gov More Cancer trials